Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jak inhibitors for moderate to severe atopic dermatitis
ChiCTR2200061505Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of upadacitinib and abrocitinib in atopic dermatitis (AD), sponsored by West China Hospital of Sichuan University. Primary endpoints: Eczema Area and Severity Index (EASI) score, Investigator’s Global Assessment (IGA) score and 4 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
upadacitinibabrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2200061505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061505.